Phase I Trial of Sorafenib in Combination With Gefitinib in Patients With Refractory or Recurrent Non Small Cell Lung Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-2889
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Ifosfamide in Patients With Recurrent Non Small Cell Lung Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
1986English

A Phase I Trial of Temsirolimus and Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer

Chemotherapy
MedicineDrug DiscoveryInfectious DiseasesOncologyPharmacology
2016English

Outcome Analysis of Phase I Trial Patients With Metastatic KRAS and/or TP53 Mutant Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

Phase II Trial of Sequential Gefitinib After Minor Response or Partial Response to Chemotherapy in Chinese Patients With Advanced Non-Small-Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy